Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 679

1.

Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.

Butler J, Zannad F, Fitchett D, Zinman B, Koitka-Weber A, von Eynatten M, Zwiener I, George J, Brueckmann M, Cheung AK, Wanner C.

Circ Heart Fail. 2019 Jun;12(6):e005875. doi: 10.1161/CIRCHEARTFAILURE.118.005875. Epub 2019 Jun 5.

PMID:
31163986
2.

Association Between Layer-Specific Longitudinal Strain and Risk Factors of Heart Failure and Dyspnea: A Population-Based Study.

Huttin O, Girerd N, Coiro S, Bozec E, Selton-Suty C, Lamiral Z, Frikha Z, Kobayashi M, Argulian E, Narula J, Fraser AG, Rossignol P, Zannad F.

J Am Soc Echocardiogr. 2019 May 16. pii: S0894-7317(19)30152-X. doi: 10.1016/j.echo.2019.03.011. [Epub ahead of print]

PMID:
31104890
3.

Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure.

Ferreira JP, Verdonschot J, Collier T, Wang P, Pizard A, Bär C, Björkman J, Boccanelli A, Butler J, Clark A, Cleland JG, Delles C, Diez J, Girerd N, González A, Hazebroek M, Huby AC, Jukema W, Latini R, Leenders J, Levy D, Mebazaa A, Mischak H, Pinet F, Rossignol P, Sattar N, Sever P, Staessen JA, Thum T, Vodovar N, Zhang ZY, Heymans S, Zannad F.

Circ Heart Fail. 2019 May;12(5):e005897. doi: 10.1161/CIRCHEARTFAILURE.118.005897.

PMID:
31104495
4.

The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study.

Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, Devalaraja M, Anker SD, Cleland JG, Dickstein K, Filippatos GS, van der Harst P, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, Zannad F, Zwinderman AH, Hillege HL, van Veldhuisen DJ, Kakkar R, Voors AA, van der Meer P.

Eur J Heart Fail. 2019 May 14. doi: 10.1002/ejhf.1482. [Epub ahead of print]

PMID:
31087601
5.

Estimated Long-Term Survival With Eplerenone.

Stienen S, Ferreira JP, Vincent J, Busselen M, Li B, McMurray JJV, Pitt B, Girerd N, Rossignol P, Zannad F.

J Am Coll Cardiol. 2019 May 14;73(18):2357-2359. doi: 10.1016/j.jacc.2019.02.043. No abstract available.

PMID:
31072582
6.

Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS case-control analyses.

Ferreira JP, Pizard A, Machu JL, Bresso E, Rocca HB, Girerd N, Leroy C, González A, Diez J, Heymans S, Devignes MD, Rossignol P, Zannad F; FIBRO-TARGETS investigators.

Clin Res Cardiol. 2019 May 6. doi: 10.1007/s00392-019-01480-4. [Epub ahead of print]

PMID:
31062082
7.

Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.

Greenberg B, Neaton JD, Anker SD, Byra WM, Cleland JGF, Deng H, Fu M, La Police DA, Lam CSP, Mehra MR, Nessel CC, Spiro TE, van Veldhuisen DJ, Vanden Boom CM, Zannad F.

JAMA Cardiol. 2019 Apr 24. doi: 10.1001/jamacardio.2019.1049. [Epub ahead of print]

PMID:
31017637
8.

Low fibrosis biomarker levels predict cardiac resynchronization therapy response.

Massoullié G, Sapin V, Ploux S, Rossignol P, Mulliez A, Jean F, Marie PY, Merlin C, Pereira B, Andronache M, Motreff P, Chabin X, Sellal JM, Citron B, Lusson JR, Vorilhon C, Clerfond G, Bordachar P, Zannad F, Eschalier R.

Sci Rep. 2019 Apr 15;9(1):6103. doi: 10.1038/s41598-019-42468-4.

9.

The continuous heart failure spectrum: moving beyond an ejection fraction classification.

Triposkiadis F, Butler J, Abboud FM, Armstrong PW, Adamopoulos S, Atherton JJ, Backs J, Bauersachs J, Burkhoff D, Bonow RO, Chopra VK, de Boer RA, de Windt L, Hamdani N, Hasenfuss G, Heymans S, Hulot JS, Konstam M, Lee RT, Linke WA, Lunde IG, Lyon AR, Maack C, Mann DL, Mebazaa A, Mentz RJ, Nihoyannopoulos P, Papp Z, Parissis J, Pedrazzini T, Rosano G, Rouleau J, Seferovic PM, Shah AM, Starling RC, Tocchetti CG, Trochu JN, Thum T, Zannad F, Brutsaert DL, Segers VF, De Keulenaer GW.

Eur Heart J. 2019 Apr 8. pii: ehz158. doi: 10.1093/eurheartj/ehz158. [Epub ahead of print]

PMID:
30957868
10.

Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative.

Stienen S, Ferreira JP, Girerd N, Duarte K, Lamiral Z, McMurray JJV, Pitt B, Dickstein K, Zannad F, Rossignol P; High-Risk Myocardial Infarction Database Initiative.

Clin Res Cardiol. 2019 Apr 5. doi: 10.1007/s00392-019-01453-7. [Epub ahead of print]

PMID:
30953180
11.

The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward.

Rossignol P, Frimat L, Zannad F.

Kidney Int. 2019 Apr;95(4):747-749. doi: 10.1016/j.kint.2018.12.006.

PMID:
30904064
12.

Heart failure drug treatment.

Rossignol P, Hernandez AF, Solomon SD, Zannad F.

Lancet. 2019 Mar 9;393(10175):1034-1044. doi: 10.1016/S0140-6736(18)31808-7. Review.

PMID:
30860029
13.

Rivaroxaban in Patients with Heart Failure. Reply.

Zannad F, Greenberg B, Fu M.

N Engl J Med. 2019 Mar 7;380(10):988-989. doi: 10.1056/NEJMc1816756. No abstract available.

PMID:
30855759
14.

Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments.

Zannad F, Ferreira JP, Pitt B.

Eur Heart J Suppl. 2019 Feb;21(Suppl A):A55-A60. doi: 10.1093/eurheartj/suy034. Epub 2019 Feb 26.

15.

Is Sacubitril/Valsartan Antifibrotic?

Zannad F, Ferreira JP.

J Am Coll Cardiol. 2019 Feb 26;73(7):807-809. doi: 10.1016/j.jacc.2018.11.041. No abstract available.

PMID:
30784674
16.

Mid-term prognostic impact of residual pulmonary congestion assessed by radiographic scoring in patients admitted for worsening heart failure.

Kobayashi M, Watanabe M, Coiro S, Bercker M, Paku Y, Iwasaki Y, Chikamori T, Yamashina A, Duarte K, Ferreira JP, Rossignol P, Zannad F, Girerd N.

Int J Cardiol. 2019 Aug 15;289:91-98. doi: 10.1016/j.ijcard.2019.01.091. Epub 2019 Feb 8.

PMID:
30770263
17.

Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial.

Ferreira JP, Abreu P, McMurray JJV, van Veldhuisen DJ, Swedberg K, Pocock SJ, Vincent J, Lins K, Rossignol P, Pitt B, Zannad F.

Eur J Heart Fail. 2019 Mar;21(3):345-351. doi: 10.1002/ejhf.1400. Epub 2019 Feb 15.

PMID:
30768732
18.

Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline.

Januzzi J, Ferreira JP, Böhm M, Kaul S, Wanner C, Brueckmann M, Petrie MC, Ofstad AP, Zeller C, George J, Fitchett D, Zannad F.

Eur J Heart Fail. 2019 Mar;21(3):386-388. doi: 10.1002/ejhf.1419. Epub 2019 Feb 14. No abstract available.

PMID:
30767353
19.

Nondipping Pattern and Cardiovascular and Renal Damage in a Population-Based Study (The STANISLAS Cohort Study).

Lopez-Sublet M, Girerd N, Bozec E, Machu JL, Ferreira JP, Zannad F, Mourad JJ, Rossignol P.

Am J Hypertens. 2019 Jun 11;32(7):620-628. doi: 10.1093/ajh/hpz020.

PMID:
30753257
20.

Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis.

Dewan P, Rørth R, Jhund PS, Ferreira JP, Zannad F, Shen L, Køber L, Abraham WT, Desai AS, Dickstein K, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, McMurray JJV; PARADIGM-HF and ATMOSPHERE Investigators.

JACC Heart Fail. 2019 Apr;7(4):336-346. doi: 10.1016/j.jchf.2018.11.005. Epub 2019 Feb 6.

21.

Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology.

de Boer RA, De Keulenaer G, Bauersachs J, Brutsaert D, Cleland JG, Diez J, Du XJ, Ford P, Heinzel FR, Lipson KE, McDonagh T, Lopez-Andres N, Lunde IG, Lyon AR, Pollesello P, Prasad SK, Tocchetti CG, Mayr M, Sluijter JPG, Thum T, Tschöpe C, Zannad F, Zimmermann WH, Ruschitzka F, Filippatos G, Lindsey ML, Maack C, Heymans S.

Eur J Heart Fail. 2019 Mar;21(3):272-285. doi: 10.1002/ejhf.1406. Epub 2019 Feb 4.

22.

Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation.

Mordi IR, Santema BT, Kloosterman M, Choy AM, Rienstra M, van Gelder I, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Metra M, Ng LL, Ouwerkerk W, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Voors AA, Lang CC.

Clin Res Cardiol. 2019 Jan 4. doi: 10.1007/s00392-018-1409-x. [Epub ahead of print]

PMID:
30610382
23.

Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate.

Chin KL, Collier T, Pocock S, Pitt B, McMurray JJV, van Veldhuisen DJ, Swedberg K, Vincent J, Zannad F, Liew D.

Clin Res Cardiol. 2019 Jan 2. doi: 10.1007/s00392-018-1410-4. [Epub ahead of print]

PMID:
30604047
24.

Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study.

Ferreira JP, Metra M, Anker SD, Dickstein K, Lang CC, Ng L, Samani NJ, Cleland JG, van Veldhuisen DJ, Voors AA, Zannad F.

Eur J Heart Fail. 2019 Feb;21(2):218-226. doi: 10.1002/ejhf.1380. Epub 2019 Jan 1.

PMID:
30600578
25.

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure.

Zannad F, Rossignol P.

Circulation. 2019 Jan 15;139(3):362-365. doi: 10.1161/CIRCULATIONAHA.118.038399. No abstract available.

PMID:
30586788
26.

Novel endotypes in heart failure: effects on guideline-directed medical therapy.

Tromp J, Ouwerkerk W, Demissei BG, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Voors AA, van der Meer P.

Eur Heart J. 2018 Dec 21;39(48):4269-4276. doi: 10.1093/eurheartj/ehy712.

PMID:
30551207
27.

Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction.

Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K, Filippatos G, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, van der Meer P, Voors AA.

Int J Cardiol. 2018 Nov 15;271:132-139. doi: 10.1016/j.ijcard.2018.04.001. Epub 2018 Jul 7.

28.

Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial).

Vaduganathan M, White WB, Charytan DM, Morrow DA, Liu Y, Zannad F, Cannon CP, Bakris GL; EXAMINE Investigators.

Am J Cardiol. 2019 Feb 1;123(3):382-391. doi: 10.1016/j.amjcard.2018.10.035. Epub 2018 Nov 6.

PMID:
30477800
29.

Echocardiographic diastolic function evolution in patients with an anterior Q-wave myocardial infarction: insights from the REVE-2 study.

Ferreira JP, Bauters C, Eschalier R, Lamiral Z, Fay R, Huttin O, Girerd N, Zannad F, Pinet F, Rossignol P.

ESC Heart Fail. 2019 Feb;6(1):70-79. doi: 10.1002/ehf2.12359. Epub 2018 Nov 20.

30.

Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable.

Cosentino F, Ceriello A, Baeres FMM, Fioretto P, Garber A, Stough WG, George JT, Grant PJ, Khunti K, Langkilde AM, Plutzky J, Rydén L, Scheen A, Standl E, Tuomilehto J, Zannad F.

Eur Heart J. 2018 Nov 16. doi: 10.1093/eurheartj/ehy677. [Epub ahead of print] No abstract available.

PMID:
30445605
31.

Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial.

Greene SJ, Fonarow GC, Solomon SD, Subacius HP, Vaduganathan M, Ambrosy AP, Fudim M, Böhm M, Maggioni AP, Lewis EF, Zannad F, Butler J.

Eur J Heart Fail. 2018 Dec;20(12):1760-1763. doi: 10.1002/ejhf.1310. Epub 2018 Nov 11. No abstract available.

PMID:
30415473
32.

Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure.

Cao TH, Jones DJL, Quinn PA, Chan DCS, Hafid N, Parry HM, Mohan M, Sandhu JK, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Metra M, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zannad F, Zwinderman AH, Voors AA, Lang CC, Ng LL.

Clin Proteomics. 2018 Nov 2;15:35. doi: 10.1186/s12014-018-9213-1. eCollection 2018.

33.

Correction to: Prognostic value of estimated plasma volume in acute heart failure in three cohort studies.

Kobayashi M, Rossignol P, Ferreira JP, Aragão I, Paku Y, Iwasaki Y, Watanabe M, Fudim M, Duarte K, Zannad F, Girerd N.

Clin Res Cardiol. 2019 May;108(5):562. doi: 10.1007/s00392-018-1390-4.

PMID:
30402715
34.

Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial.

White WB, Jalil F, Cushman WC, Bakris GL, Bergenstal R, Heller SR, Liu Y, Mehta C, Zannad F, Cannon CP.

J Am Heart Assoc. 2018 Oct 16;7(20):e009114. doi: 10.1161/JAHA.118.009114.

35.

Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure (from BIOSTAT-CHF).

Suzuki T, Yazaki Y, Voors AA, Jones DJL, Chan DCS, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Lang CC, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Metra M, Ng LL.

Eur J Heart Fail. 2018 Oct 29. doi: 10.1002/ejhf.1338. [Epub ahead of print]

PMID:
30370976
36.

Diagnostic and prognostic value of plasma volume status at emergency department admission in dyspneic patients: results from the PARADISE cohort.

Chouihed T, Rossignol P, Bassand A, Duarte K, Kobayashi M, Jaeger D, Sadoune S, Buessler A, Nace L, Giacomin G, Hutter T, Barbé F, Salignac S, Jay N, Zannad F, Girerd N.

Clin Res Cardiol. 2019 May;108(5):563-573. doi: 10.1007/s00392-018-1388-y. Epub 2018 Oct 28.

PMID:
30370469
37.

Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points.

Greene SJ, Hernandez AF, Sun JL, Butler J, Armstrong PW, Ezekowitz JA, Zannad F, Ferreira JP, Coles A, Metra M, Voors AA, Califf RM, O'Connor CM, Mentz RJ.

Circ Cardiovasc Qual Outcomes. 2018 Oct;11(10):e004783. doi: 10.1161/CIRCOUTCOMES.118.004783.

PMID:
30354576
38.

Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure.

Greene SJ, Mentz RJ, Fiuzat M, Butler J, Solomon SD, Ambrosy AP, Mehta C, Teerlink JR, Zannad F, O'Connor CM.

Circulation. 2018 Sep 4;138(10):1039-1053. doi: 10.1161/CIRCULATIONAHA.118.034668.

PMID:
30354535
39.

Cardiorenal Syndrome Revisited.

Zannad F, Rossignol P.

Circulation. 2018 Aug 28;138(9):929-944. doi: 10.1161/CIRCULATIONAHA.117.028814.

PMID:
30354446
40.

Prognostic value of estimated plasma volume in acute heart failure in three cohort studies.

Kobayashi M, Rossignol P, Ferreira JP, Aragão I, Paku Y, Iwasaki Y, Watanabe M, Fudim M, Duarte K, Zannad F, Girerd N.

Clin Res Cardiol. 2019 May;108(5):549-561. doi: 10.1007/s00392-018-1385-1. Epub 2018 Oct 19. Erratum in: Clin Res Cardiol. 2018 Nov 6;:.

PMID:
30341579
41.

Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study.

Ferreira JP, Metra M, Mordi I, Gregson J, Ter Maaten JM, Tromp J, Anker SD, Dickstein K, Hillege HL, Ng LL, van Veldhuisen DJ, Lang CC, Voors AA, Zannad F.

Eur J Heart Fail. 2019 Jan;21(1):112-120. doi: 10.1002/ejhf.1323. Epub 2018 Oct 19.

PMID:
30338883
42.

Patient-reported and morbidity-mortality endpoints: can one have the best of both worlds?

Ferreira JP, Zannad F.

Eur J Heart Fail. 2019 Jan;21(1):71-73. doi: 10.1002/ejhf.1317. Epub 2018 Oct 2. No abstract available.

PMID:
30280452
43.

Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial.

Ferreira JP, Barros A, Pitt B, Montalescot G, de Sa EL, Hamm CW, Flather M, Verheugt F, Shi H, Leite-Moreira A, Vincent J, Rossignol P, Zannad F.

Clin Res Cardiol. 2018 Dec;107(12):1192-1195. doi: 10.1007/s00392-018-1373-5. Epub 2018 Sep 27. No abstract available.

PMID:
30264283
44.

Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials.

Rossello X, Ariti C, Pocock SJ, Ferreira JP, Girerd N, McMurray JJV, Van Veldhuisen DJ, Pitt B, Zannad F.

Clin Res Cardiol. 2019 May;108(5):477-486. doi: 10.1007/s00392-018-1378-0. Epub 2018 Sep 27.

PMID:
30264282
45.

Editor's Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction.

Rossello X, Ferreira JP, McMurray JJ, Aguilar D, Pfeffer MA, Pitt B, Dickstein K, Girerd N, Rossignol P, Zannad F; High-Risk Myocardial Infarction Database Initiative.

Eur Heart J Acute Cardiovasc Care. 2019 Apr;8(3):231-241. doi: 10.1177/2048872618803701. Epub 2018 Sep 27.

PMID:
30259764
46.

Heart rate, pulse pressure and mortality in patients with myocardial infarction complicated by heart failure.

Dobre D, Kjekshus J, Rossignol P, Girerd N, Benetos A, Dickstein K, Zannad F.

Int J Cardiol. 2018 Nov 15;271:181-185. doi: 10.1016/j.ijcard.2018.05.017.

PMID:
30223350
47.

Correction to: Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients.

Léopold V, Gayat E, Pirracchio R, Spinar J, Parenica J, Tarvasmäki T, Lassus J, Harjola VP, Champion S, Zannad F, Valente S, Urban P, Chua HR, Bellomo R, Popovic B, Ouweneel DM, Henriques JPS, Simonis G, Lévy B, Kimmoun A, Gaudard P, Basir MB, Markota A, Adler C, Reuter H, Mebazaa A, Chouihed T.

Intensive Care Med. 2018 Nov;44(11):2022-2023. doi: 10.1007/s00134-018-5372-9.

PMID:
30215188
48.

Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction.

Tromp J, Westenbrink BD, Ouwerkerk W, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Lang CC, Ng LL, Zannad F, Zwinderman AH, Hillege HL, van der Meer P, Voors AA.

J Am Coll Cardiol. 2018 Sep 4;72(10):1081-1090. doi: 10.1016/j.jacc.2018.06.050.

PMID:
30165978
49.

Health-related determinants of undiagnosed arterial hypertension: a population-based study.

Chau K, Girerd N, Zannad F, Rossignol P, Boivin JM.

Fam Pract. 2019 May 23;36(3):276-283. doi: 10.1093/fampra/cmy075.

PMID:
30165649
50.

Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.

Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, Lam CSP, Mehra MR, Neaton JD, Nessel CC, Spiro TE, van Veldhuisen DJ, Greenberg B; COMMANDER HF Investigators.

N Engl J Med. 2018 Oct 4;379(14):1332-1342. doi: 10.1056/NEJMoa1808848. Epub 2018 Aug 27.

Supplemental Content

Loading ...
Support Center